Abstract:4107 Background: This multicenter, nonrandomized phase II study was launched to evaluate the efficacy and safety of cetuximab in combination with modified FOLFIRI as second-line treatment for advanced gastric cancer patients. Methods: Inclusion criteria were: 18-70 years, ECOG PS ≤ 1, histologically confirmed adenocarcinoma of stomach and failure to first-line therapy. C225 was given at an initial dose of 400 mg/m2, followed by weekly infusions of 250 mg/m2. On day 2 of each 14-day period, patients received CPT-11 at a dose of 180 mg/m2; CF at a dose of 200 mg/m2; and 5-Fu as a bolus of 400 mg/m2 and then 2,400 mg/m2 by continuous infusion for 46 hours. Treatment was continued until disease progression, unacceptable toxic effects, or withdrawal of consent. The study was carried out according to the Gehan's two- stage phase II trial design, the planned sample size was 55. The primary endpoint was TTP. Secondary endpoints included RR, OS and AEs. Results: Sixty-one patients were enrolled: 34 males (56%), 27 females (44%); median age was 52 years (range 26-69). 7 patients discontinued without tumor assessment within first cycle of treatment: 1 patient for obstructive jaundice, 3 patients for unacceptable grade 4 febrile neutropenia, 3 patients for intestinal obstruction, and 5 patients are too early to evaluate. 56 patients were evaluable for safety and 49 patients were evaluable for efficacy evaluation. The median TTP was 4.9 months (95% CI: 3.9-5.9 months). Objective responses (RECIST) were: 1 (2.0%) CR, 16 (32.7%) PR, 17 (34.7%) CR + PR, 25 (51.0%) SD, 7 (14.3%) PD. The median OS was 8.1 months (95% CI: 7.2-9.0 months). Grade 3-4 toxicity (CTC v3.0) was 62.5% neutropenia (12.5% febrile neutropenia), 26.8% anemia, 5.4% thrombocytopenia, 8.9% asthenia, 5.4% vomiting, 3.6% diarrhea, 3.6 % fatigue, 1.8% elevated transaminase and 1.8% allergic reaction. Skin reactions ≥ 2 was observed in 42.9%. Conclusions: The combination of cetuximab and FOLFIRI was well-tolerated and appears to be active (85.7% of disease control rate) as second-line treatment for advanced gastric cancer patients. Further analysis of this study will allow more detailed assessment of this combination treatment. No significant financial relationships to disclose.

Short-term Efficacy of Cetuximab-Contained Regimen on Patients with Advanced Gastric and Esophageal Cancer

China Special Issue on Gastrointestinal Tumors‐cetuximab Retreatment Plus Camrelizumab and Liposomal Irinotecan in Patients with RAS Wild‐type Metastatic Colorectal Cancer: Cohort B of the Phase II CRACK Study

Predictive biomarkers for the efficacy of cetuximab combined with cisplatin and capecitabine in advanced gastric or esophagogastric junction adenocarcinoma: a prospective multicenter phase 2 trial

[Cetuximab in Combination with Chemotherapy for Patients with Gastrointestinal Cancer].

Cetuximab Combined with FOLFOX4 As the First-Line Treatment for Advanced Gastric Cancer: Report of 25 Cases from a Single Institution

Effect of cetuximab plus FOLFOX4 regimen on clinical outcomes in advanced gastric carcinoma patients receiving evidence-based care

EGFR Expression Level Predicts Response and Overall Survival in Gastric Cancer PDTX Model Treated with Cetuximab

A Meta-Analysis of Clinical Trials over Regimens with or Without Cetuximab for Advanced Gastric Cancer Patients.

EGFR Gene Status Predicts Response and Survival Benefit in a Preclinical Gastric Cancer Trial Treating Patient-Derived Xenografts with Cetuximab

Phase Ii Study of Cetuximab in Combination with Modified Folfiri in Patients with Advanced Gastric Cancer Who Failed First-Line Chemotherapy (effi Study)

Cetuximab enhances the activities of irinotecan on gastric cancer cell lines through downregulating the EGFR pathway upregulated by irinotecan

Clinical Progress of Anti-Epidermal Growth Factor Receptor Antibody,cetuximab, in the Treatment of Colorectal Cancer

Retrospective study on regimens of capecitabine-based chemotherapy in the treatment for advanced gastric cancer

Cetuximab Combined with Concurrent Chemoradiotheray in Chinese Patients with Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma: A Prospective, Multicenter Phase II Trial.

K-ras status and efficacy of cetuximab-containing regimen in the treatment of patients with metastatic colorectal cancer

Effect of cetuximab combined with FUFOX regimen in treatment of patients with advanced colorectal cancer

A Subset of Gastric Cancers with EGFR Amplification and Overexpression Respond to Cetuximab Therapy

Retrospective Study of Cetuximab in Combination with Chemotherapy for Patients with Colorectal Cancer

Efficacy and Immune Mechanisms of Cetuximab for the Treatment of Metastatic Colorectal Cancer

Standard Chemotherapy with Cetuximab for Treatment of Colorectal Cancer

A multi-center phase II study and biomarker analysis of combined cetuximab and modified FOLFIRI as second-line treatment in patients with metastatic gastric cancer